Metabolic Modulation of Glioblastoma with Dichloroacetate

Метаболическая модуляция глиобластомы с помощью дихлорацетата
Peter Dromparis, Evangelos D. Michelakis, Alois Haromy, Michael Sean McMurtry, Gopinath Sutendra, John Robert Mackey, L. Webster, Eric B. Niven, C. Maguire, T.-L. Gammer, Dorcas S. Fulton, Bassam Abdulkarim, Kenneth C. Petruk
2010-05-12

Dichloroacetate (DCA)GlioblastomaGlioblastoma stem cellsMitochondrial hyperpolarizationPyruvate dehydrogenase kinase II
Solid tumors, including the aggressive primary brain cancer glioblastoma multiforme, develop resistance to cell death, in part as a result of a switch from mitochondrial oxidative phosphorylation to cytoplasmic glycolysis. This metabolic remodeling is accompanied by mitochondrial hyperpolarization. We tested whether the small-molecule and orphan drug dichloroacetate (DCA) can reverse this cancer-specific metabolic and mitochondrial remodeling in glioblastoma. Freshly isolated glioblastomas from 49 patients showed mitochondrial hyperpolarization, which was rapidly reversed by DCA. In a separate experiment with five patients who had glioblastoma, we prospectively secured baseline and serial tumor tissue, developed patient-specific cell lines of glioblastoma and putative glioblastoma stem cells (CD133(+), nestin(+) cells), and treated each patient with oral DCA for up to 15 months. DCA depolarized mitochondria, increased mitochondrial reactive oxygen species, and induced apoptosis in GBM cells, as well as in putative GBM stem cells, both in vitro and in vivo. DCA therapy also inhibited the hypoxia-inducible factor-1alpha, promoted p53 activation, and suppressed angiogenesis both in vivo and in vitro. The dose-limiting toxicity was a dose-dependent, reversible peripheral neuropathy, and there was no hematologic, hepatic, renal, or cardiac toxicity. Indications of clinical efficacy were present at a dose that did not cause peripheral neuropathy and at serum concentrations of DCA sufficient to inhibit the target enzyme of DCA, pyruvate dehydrogenase kinase II, which was highly expressed in all glioblastomas. Metabolic modulation may be a viable therapeutic approach in the treatment of glioblastoma.
1
DCA depolarized mitochondria, increased mitochondrial reactive oxygen species, and induced apoptosis in glioblastoma cells and putative glioblastoma stem cells in vitro and in vivo.
2
DCA inhibited hypoxia-inducible factor-1α, promoted p53 activation, and suppressed angiogenesis in glioblastoma models.
3
Dose-limiting toxicity was dose-dependent, reversible peripheral neuropathy, without hematologic, hepatic, renal, or cardiac toxicity; pyruvate dehydrogenase kinase II was highly expressed in all tumors.
4
Glioblastomas from 49 patients exhibited mitochondrial hyperpolarization, which was rapidly reversed by dichloroacetate (DCA).
5
In five patients treated orally for up to 15 months, DCA showed indications of clinical efficacy at non-neuropathic doses and target-inhibitory serum concentrations.

glioblastoma multiforme tumors and derived glioblastoma cells, including putative glioblastoma stem cells

Dichloroacetate-induced reversal of tumor-specific metabolic and mitochondrial remodeling, with effects on apoptosis, hypoxia signaling, p53 activation, angiogenesis, toxicity, and clinical efficacy

Publication Details
Publication Date
2010-05-12
Journal
Publisher
ISSN
Cited by
790
Access Type
Author Information
Authors
Peter Dromparis
Evangelos D. Michelakis
Alois Haromy
Michael Sean McMurtry
Gopinath Sutendra
John Robert Mackey
L. Webster
Eric B. Niven
C. Maguire
T.-L. Gammer
Dorcas S. Fulton
Bassam Abdulkarim
Kenneth C. Petruk
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%